Categories: Health

EU regulator rejects Alzheimer’s drug lecanemab


Prof Tara Spires-Jones, president of the British Neuroscience Association, said the EMA’s decision will come as “a disappointment to many”.

But she said there were reasons to remain hopeful.

“Lecanemab has shown that it is possible to slow down disease progression, and research does work. Now we need to ramp up our efforts to discover new and safer treatments,” Prof Spires-Jones said.

Prof John Hardy, professor of neuroscience and group leader at the UK Institute for Dementia Research, University College London (UCL), said the decision could have unintended consequences.

“I am sure we will now see rich people with early Alzheimer’s disease flying to the US or other jurisdictions for treatment.”



Source link

gulftimes

Recent Posts

Arab News | Canada defense chief sees no change despite reported US military curbs

HALIFAX, Nova Scotia: Canadian Defense Minister David McGuinty said on Saturday he had seen no…

56 minutes ago

Arab News | Fossil fuel dispute threatens to scupper climate deal

ANTALYA, Turkiye: Global climate talks dragged into a second day of overtime Sunday as a…

2 hours ago

Arab News | Belgium faces air traffic shutdown due to national strike Monday

BRUSSELS, Belgium: Almost all flights are set to be canceled in Belgium on Monday after…

2 hours ago

Arab News | Democrats who swept into the Senate promised change. A leadership vote is testing them early

WASHINGTON: The Democratic Party’s incoming senators haven’t even been sworn into office yet, but the…

2 hours ago

Arab News | Libya loses $30.8 million as armed group blocks oil pipeline for over 20 days

TRIPOLI: Libya has lost more than $30.8 million in oil revenue after an armed group…

3 hours ago

Arab News | ‘We lost everything’: Brazil town clears rubble after deadly storm

TUPANCIRETÃ, Brazil: Residents of a town in southern Brazil picked through the wreckage of their…

3 hours ago